Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Aurobindo Pharma Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

23 Jul 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - Aurobindo Pharma Ltd (AUROPHARMA-IN)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

29 Jul 2016 Thomson Reuters Stock Report 11 $25.00

Aurobindo Pharma Ltd (AUROPHARMA) - Financial Analysis Review

Aurobindo Pharma Ltd (AUROPHARMA) - Financial Analysis Review Summary Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceut...

21 Jul 2016 GlobalData 64 $300.00

Company Snapshot - Aurobindo Pharma Limited

A director at Aurobindo Pharma Limited sold 47,400 shares at 0.000INR and the significance rating of the trade was 86/100. I...

18 Jul 2016 Directors Deals Ltd. 1 $12.00

Wright Investors Service Comprehensive Report for Aurobindo Pharma Ltd

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

11 Jul 2016 Wright Reports 60 $75.00

Aurobindo Pharma Ltd: Downgraded to Average

30 Jun 2016 Sadif Analytics Prime 3 $10.00

MOSL: THE CORNER OFFICE— Aurobindo Pharma | Verson 2.0 – Bigger, Better, Stronger-Size of a leader + growth of a start-up

THE CORNER OFFICE— Aurobindo Pharma | Verson 2.0 – Bigger, Better, Stronger; Size of a leader + growth of a start-up Mr PV...

29 Jun 2016 Motilal Oswal Securities Ltd. 14 $127.00

Aurobindo Pharma Ltd (AUROPHARMA) - Financial Analysis Review

Aurobindo Pharma Ltd (AUROPHARMA) - Financial Analysis Review Summary Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceut...

17 Jun 2016 GlobalData 57 $300.00

MOSL: AUROBINDO PHARMA 4QFY16 (Buy)-Results in line with estimates-US business’ growth momentum to continue

AUROBINDO PHARMA 4QFY16: Results in line with estimates; US business’ growth momentum to continue (ARBP IN, Mkt Cap USD6.8b,...

01 Jun 2016 Motilal Oswal Securities Ltd. 12 $115.00

Aurobindo Pharma (ARBP)_Q4FY16 Result Update

Aurobindo Pharma’s (ARBP) financial performance for Q4FY16 was marginally below our estimates. Net sales increased by 17% y-y...

01 Jun 2016 IndiaNivesh Securities Pvt Ltd 7 $69.00